NO992102L - Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen - Google Patents

Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen

Info

Publication number
NO992102L
NO992102L NO992102A NO992102A NO992102L NO 992102 L NO992102 L NO 992102L NO 992102 A NO992102 A NO 992102A NO 992102 A NO992102 A NO 992102A NO 992102 L NO992102 L NO 992102L
Authority
NO
Norway
Prior art keywords
composition
peptide composition
well
peptide
cancer vaccine
Prior art date
Application number
NO992102A
Other languages
English (en)
Other versions
NO309798B1 (no
NO992102D0 (no
Inventor
Jon Amund Eriksen
Marianne Klemp Gjertsen
Gustav Gaudernack
Mona Moeller
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Priority to NO19992102A priority Critical patent/NO309798B1/no
Publication of NO992102D0 publication Critical patent/NO992102D0/no
Priority to JP2000615037A priority patent/JP2002543149A/ja
Priority to EP00925746A priority patent/EP1173199A1/en
Priority to AU44389/00A priority patent/AU4438900A/en
Priority to CA002372187A priority patent/CA2372187A1/en
Priority to ARP000102059A priority patent/AR023806A1/es
Priority to PCT/NO2000/000142 priority patent/WO2000066153A1/en
Publication of NO992102L publication Critical patent/NO992102L/no
Publication of NO309798B1 publication Critical patent/NO309798B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19992102A 1999-04-30 1999-04-30 Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen NO309798B1 (no)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NO19992102A NO309798B1 (no) 1999-04-30 1999-04-30 Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
JP2000615037A JP2002543149A (ja) 1999-04-30 2000-04-28 ＲＡＳオンコージンｐ２１ペプチドワクチン
EP00925746A EP1173199A1 (en) 1999-04-30 2000-04-28 RAS ONCOGEN p21 PEPTIDE VACCINES
AU44389/00A AU4438900A (en) 1999-04-30 2000-04-28 Ras oncogen p21 peptide vaccines
CA002372187A CA2372187A1 (en) 1999-04-30 2000-04-28 Ras oncogen p21 peptide vaccines
ARP000102059A AR023806A1 (es) 1999-04-30 2000-04-28 Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
PCT/NO2000/000142 WO2000066153A1 (en) 1999-04-30 2000-04-28 RAS ONCOGEN p21 PEPTIDE VACCINES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19992102A NO309798B1 (no) 1999-04-30 1999-04-30 Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen

Publications (3)

Publication Number Publication Date
NO992102D0 NO992102D0 (no) 1999-04-30
NO992102L true NO992102L (no) 2000-10-31
NO309798B1 NO309798B1 (no) 2001-04-02

Family

ID=19903274

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992102A NO309798B1 (no) 1999-04-30 1999-04-30 Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen

Country Status (7)

Country Link
EP (1) EP1173199A1 (no)
JP (1) JP2002543149A (no)
AR (1) AR023806A1 (no)
AU (1) AU4438900A (no)
CA (1) CA2372187A1 (no)
NO (1) NO309798B1 (no)
WO (1) WO2000066153A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836684B1 (fr) * 2002-03-04 2004-12-17 Inst Nat Sante Rech Med Peptides ras mutes et leur utilisation en immunotherapie
CN102370974B (zh) 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
BRPI0709340A2 (pt) 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
PE20161551A1 (es) * 2009-09-03 2017-01-18 Pfizer Vaccines Llc Vacuna de pcsk9
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
CN102060929A (zh) * 2010-06-07 2011-05-18 夏书奇 T细胞免疫平衡肽
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3369432A1 (en) 2013-12-09 2018-09-05 Targovax Asa A peptide mixture
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CA2947963A1 (en) * 2014-05-06 2015-11-12 Targovax Asa Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
TW202523682A (zh) * 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
RU2018101225A (ru) * 2015-06-16 2019-07-16 Тарговакс Аса Мутированные фрагменты белка ras
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
US12303561B2 (en) 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
WO2020145222A1 (ja) * 2019-01-07 2020-07-16 地方独立行政法人神奈川県立病院機構 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬
IL266728B (en) * 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
IL295624A (en) * 2020-02-19 2022-10-01 Aelin Therapeutics Molecules targeting proteins
US20230100941A1 (en) * 2020-02-19 2023-03-30 Aelin Therapeutics Molecules targeting mutant ras protein
WO2022219152A1 (en) * 2021-04-16 2022-10-20 Oblique Therapeutics Ab Kras antibodies
US20250332239A1 (en) * 2022-11-22 2025-10-30 Elixirgen Therapeutics, Inc. Antigens for cancer immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
ATE220718T1 (de) * 1996-04-19 2002-08-15 Us Gov Sec Health Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer

Also Published As

Publication number Publication date
NO309798B1 (no) 2001-04-02
NO992102D0 (no) 1999-04-30
JP2002543149A (ja) 2002-12-17
EP1173199A1 (en) 2002-01-23
AR023806A1 (es) 2002-09-04
AU4438900A (en) 2000-11-17
WO2000066153A1 (en) 2000-11-09
CA2372187A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
NO992102L (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
NL1015859A1 (nl) Farmaceutische preparaten.
NO20032438D0 (no) Orto- og metasubstituerte bis-arylforbindelser, deres fremstilling og anvendelse samt farmasöytiske preparater inneholdende forbindelsene
DK1210113T3 (da) Kombinerede vaccinepræparater
ITTO20010005A0 (it) Formulazione farmaceutica.
NO20033556D0 (no) Farmasöytiske preparater
EE200200038A (et) Konservitud farmatseutilised preparaadid
TR199901077A3 (tr) Ispençiyari formülasyonlar.
KR20050009999A (ko) 약제학적 제제
NO20015175D0 (no) Farmasöytisk sammensetning
DE60045324D1 (de) Impfstoffzusammensetzung
ZA200407868B (en) 17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations.
NO20006138D0 (no) Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20022606L (no) Farmasöytiske kombinasjoner
NO20016247D0 (no) Streptograminderivater, deres fremstilling og preparater inneholdende derivatene
IT1311921B1 (it) Composti farmaceutici.
NO20022022D0 (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
DE69926012D1 (de) Arzneizubereitungen
DK1118610T3 (da) Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
AR025867A1 (es) Formulacion portasdora farmaceutica
FI4488U1 (fi) Farmaseuttinen koostumus
NO20014692L (no) 3-amidinobenzensulfonamidderivater, medisinske sammensetninger inneholdende slike samt intermediater vedfremstillingen derav
EE200100697A (et) Farmatseutiline kompleks

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS POSTBOKS 765 SENTRUM OSLO, 0106 NO

MM1K Lapsed by not paying the annual fees